US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Hemab Therapeutics Holdings, Inc.

30.84

-1.7600-5.40%

Pre-market: 31.210.3700+1.20%04:01 EDT

Volume:865.20K

Turnover:27.68M

Market Cap:1.44B

PE:-17.31

High:33.27

Open:32.92

Low:30.80

Close:32.60

52wk High:55.42

52wk Low:23.00

Shares:46.71M

Float Shares:16.75M

Volume Ratio:2.29

T/O Rate:5.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7820

EPS(LYR):-67.5613

ROE:-46.99%

ROA:-30.11%

PB:3.17

PE(LYR):-0.46

Loading ...

Overview Company News Filings

Hemab Therapeutics Names Keli Walbert to Board, Adds Her to Audit Committee

Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert

THOMSON REUTERS

Hemab Therapeutics Doses First Volunteer in Phase 1 HMB-003 Study

MT Newswires Live

Hemab Therapeutics doses first patient in HMB-003 trial

Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of Hmb-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding

THOMSON REUTERS

Hemab Therapeutics Holdings, Inc. (COAG) Gets a Buy from Wedbush

U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage

Hemab Therapeutics' Q2 Net Loss Narrows

MT Newswires Live

Earnings Flash (COAG) Hemab Therapeutics Posts Q2 Net Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss

MT Newswires Live

Hemab Therapeutics - Q2 Net Loss $24.20 Mln, or $0.80 Per Share

THOMSON REUTERS

Press Release: Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics' Sutacimig Continues to Support Durable Bleed Reduction, Wedbush Says

MT Newswires Live

Hemab Therapeutics presents sutacimig data at ISTH Congress

Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says

MT Newswires Live

Hemab Therapeutics Holdings Inc : Jefferies Raises Target Price to $47 from $39

THOMSON REUTERS

Hemab Therapeutics presents new clinical data from HMB-002 in VWD

Hemab Therapeutics Plans First-in-human Study of Hmb-003 Plasmin Inhibitor in 2H 2026

Major Investor Quietly Ramps Up Stake in Hemab Therapeutics

RA Capital Management reports Hemab Therapeutics common stock purchase worth $1.69 million

Hemab Therapeutics Hldgs Initiated at Buy by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/COAG/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"COAG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COAG\",,,,,undefined,":{"symbol":"COAG","market":"US","secType":"STK","nameCN":"Hemab Therapeutics Holdings, Inc.","latestPrice":30.84,"timestamp":1790798400000,"preClose":32.6,"halted":0,"volume":865203,"hourTrading":{"tag":"盘前","latestPrice":31.21,"preClose":30.84,"latestTime":"04:01 EDT","volume":36,"amount":1123.56,"timestamp":1790841666746,"change":0.37,"changeRate":0.011997,"amplitude":0},"delay":0,"changeRate":-0.053987730061349735,"floatShares":16750000,"shares":46705400,"eps":-1.782,"marketStatus":"Pre-Mkt","change":-1.76,"latestTime":"10-01 07:38:13 EDT","open":32.92,"high":33.27,"low":30.8,"amount":27680548.594578,"amplitude":0.075767,"askPrice":39.29,"askSize":100,"bidPrice":25.61,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.782,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":30.84,"preHourTrading":{"tag":"盘前","latestPrice":31.21,"preClose":30.84,"latestTime":"04:01 EDT","volume":36,"amount":1123.56,"timestamp":1790841666746,"change":0.37,"changeRate":0.011997,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":30.84,"preClose":30.84,"latestTime":"19:30 EDT","volume":3554,"amount":109605.36,"timestamp":1790811003525,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.2943900087964635},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COAG\",,,,,undefined,":{"symbol":"COAG","floatShares":16750000,"roa":"-30.11%","roe":"-46.99%","lyrEps":-67.56131,"volumeRatio":2.2943900087964635,"shares":46705400,"dividePrice":0,"high":33.27,"amplitude":0.075767,"preClose":32.6,"low":30.8,"week52Low":23.0001,"pbRate":"3.17","week52High":55.42,"institutionHeld":0,"latestPrice":30.84,"eps":-1.782,"divideRate":0,"volume":865203,"delay":0,"ttmEps":-1.782,"open":32.92,"prevYearClose":18,"prevWeekClose":34.74,"prevMonthClose":30.84,"prevQuarterClose":30.84,"fiveDayClose":36.73,"twentyDayClose":44.02,"sixtyDayClose":31.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COAG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"COAG","fiscalQuarterEnding":"2026/06","expectedEps":-0.63,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COAG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"COAG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1781755200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/COAG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"COAG","date":"2026-09-30","current":-17.306397,"percent":0.796117,"low":-34.170536,"twenty":-29.229697,"median":-22.291319,"eighty":-18.292807,"high":-11.042152,"avg":-23.38295,"sd":5.22585,"marketCap":1522815014},"quantilePoints":[{"date":"2026-05-01","current":-11.042152,"twenty":-11.042152,"median":-11.042152,"eighty":-11.042152,"marketCap":705737088},{"date":"2026-05-08","current":-17.79803,"twenty":-17.79803,"median":-17.407359,"eighty":-17.286354,"marketCap":1137525503},{"date":"2026-05-15","current":-19.616555,"twenty":-19.616555,"median":-17.521449,"eighty":-17.286354,"marketCap":1253752856},{"date":"2026-05-22","current":-18.185245,"twenty":-19.409118,"median":-17.853347,"eighty":-17.293269,"marketCap":1162273533},{"date":"2026-05-29","current":-19.360717,"twenty":-19.450605,"median":-18.046954,"eighty":-17.354117,"marketCap":1237401480},{"date":"2026-06-05","current":-17.56985,"twenty":-19.450605,"median":-18.185245,"eighty":-17.491025,"marketCap":1122941843},{"date":"2026-06-12","current":-18.627775,"twenty":-19.370397,"median":-18.1403,"eighty":-17.515917,"marketCap":1190556995},{"date":"2026-06-18","current":-18.288963,"twenty":-19.294337,"median":-18.002009,"eighty":-17.444006,"marketCap":1168902469},{"date":"2026-06-26","current":-18.159648,"twenty":-19.492093,"median":-18.185245,"eighty":-17.510385,"marketCap":1294673965},{"date":"2026-07-02","current":-21.291074,"twenty":-19.764526,"median":-18.302792,"eighty":-17.540809,"marketCap":1517925825},{"date":"2026-07-10","current":-24.370091,"twenty":-20.501011,"median":-18.714206,"eighty":-17.578148,"marketCap":1737441252},{"date":"2026-07-17","current":-29.172047,"twenty":-21.688778,"median":-18.837687,"eighty":-17.609955,"marketCap":2079791907},{"date":"2026-07-24","current":-30.02369,"twenty":-24.062189,"median":-19.305401,"eighty":-17.650059,"marketCap":2140508940},{"date":"2026-07-31","current":-31.09807,"twenty":-25.689482,"median":-19.512836,"eighty":-17.666654,"marketCap":2217105812},{"date":"2026-08-07","current":-34.170536,"twenty":-29.287346,"median":-19.706444,"eighty":-17.692929,"marketCap":2436154185},{"date":"2026-08-14","current":-30.277152,"twenty":-30.021629,"median":-19.996854,"eighty":-17.818774,"marketCap":2520118712},{"date":"2026-08-21","current":-27.050208,"twenty":-30.064832,"median":-20.629413,"eighty":-17.903131,"marketCap":2251524039},{"date":"2026-08-28","current":-27.774166,"twenty":-30.021629,"median":-21.296443,"eighty":-17.946001,"marketCap":2311782670},{"date":"2026-09-04","current":-24.900782,"twenty":-29.906697,"median":-22.201677,"eighty":-18.108214,"marketCap":2072616631},{"date":"2026-09-11","current":-22.38096,"twenty":-29.479949,"median":-23.509442,"eighty":-18.159648,"marketCap":1862879225},{"date":"2026-09-18","current":-23.132978,"twenty":-29.429728,"median":-22.852375,"eighty":-18.185245,"marketCap":1925473462},{"date":"2026-09-25","current":-20.046337,"twenty":-29.316171,"median":-22.510038,"eighty":-18.288963,"marketCap":1668556819},{"date":"2026-09-30","current":-18.295369,"twenty":-29.229697,"median":-22.291319,"eighty":-18.292807,"marketCap":1522815014}],"updateTime":1790853864273},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"COAG\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670490032","title":"Hemab Therapeutics Names Keli Walbert to Board, Adds Her to Audit Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2670490032","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670490032?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:01","pubTimestamp":1790280077,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics names Keli Walbert to board, adds her to audit committeeHemab Therapeutics appointed Keli Walbert to its board, effective Sept. 24, 2026.Walbert will join the board’s Audit Committe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nNDL3HZbnc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670949008","title":"Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert","url":"https://stock-news.laohu8.com/highlight/detail?id=2670949008","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670949008?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:01","pubTimestamp":1790280060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA636KQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668627719","title":"Hemab Therapeutics Doses First Volunteer in Phase 1 HMB-003 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2668627719","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668627719?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:43","pubTimestamp":1789648983,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics  dosed the first healthy volunteer in a phase 1 trial evaluating investigational HMB-003 for heavy menstrual bleeding, the company said Thursday.HMB-003 showed greater activity than tranexamic acid in preclinical models, while a single subcutaneous dose in minipigs provided about one week of sustained antifibrinolytic activity, the company said.The randomized, placebo-controlled trial is assessing HMB-003's safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adults.Hemab expects to report results by mid-2027 that will inform development plans for heavy menstrual bleeding and other bleeding conditions, it added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COAG","LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668196234","title":"Hemab Therapeutics doses first patient in HMB-003 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668196234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668196234?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:05","pubTimestamp":1789646751,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics (COAG) announced that the first healthy volunteer has been dosed in its Phase 1 clinical trial evaluating HMB-003, an investigat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-doses-first-patient-in-hmb-003-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-doses-first-patient-in-hmb-003-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","MEDX","LENZ","BK4007","HYLG","COAG","BK4539","NVIB","BK4139","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668964648","title":"Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of Hmb-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding","url":"https://stock-news.laohu8.com/highlight/detail?id=2668964648","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668964648?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:00","pubTimestamp":1789646401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA5SQYCP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903312","title":"Hemab Therapeutics Holdings, Inc. (COAG) Gets a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903312?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:55","pubTimestamp":1786542934,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten maintained a Buy rating on Hemab Therapeutics Holdings, Inc. today and set a price target of $64.00. According t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/hemab-therapeutics-holdings-inc-coag-gets-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/hemab-therapeutics-holdings-inc-coag-gets-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658276289","title":"U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage","url":"https://stock-news.laohu8.com/highlight/detail?id=2658276289","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658276289?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:07","pubTimestamp":1786522040,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public StorageAug 12 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, inclu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N4490GI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FXU","TXG","LITE","RSPS","PNW","CVS","SGMT","LOW","CUBE","NTRA","TGT","AMBQ","ACM","BCAX","LPTH","HLIO","ACVA","BBIO","CAVA","FLUT","AUAU","MDLN","PSA","CRCL","NEM","MRCY","JAZZ","GAP","EXR","MAA","LEGN","CANC","LBRX","RPD","SR","CRWV","LENZ","MNST","ANF","ARKG","CAH","EGGY","HD","JBIO","BLCK","GDX","REZ","LAZR","ODDZ","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997813","title":"Hemab Therapeutics' Q2 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997813","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997813?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:33","pubTimestamp":1786447990,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics (COAG) reported a Q2 net loss Tuesday of $0.80 per diluted share, narrowing from a $12.91 loss per share a year earlier.One analyst polled by FactSet expected a $0.56 loss per share.No revenue was reported for the period.Hemab Therapeutics shares were down 1.7% premarket Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COAG","LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992182","title":"Earnings Flash (COAG) Hemab Therapeutics Posts Q2 Net Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992182","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992182?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:16","pubTimestamp":1786446960,"startTime":"0","endTime":"0","summary":"Earnings Flash (COAG) Hemab Therapeutics Posts Q2 Net Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658532992","title":"Hemab Therapeutics - Q2 Net Loss $24.20 Mln, or $0.80 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2658532992","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658532992?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUA6KZQ4F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658899239","title":"Press Release: Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658899239","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658899239?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446000,"startTime":"0","endTime":"0","summary":"Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, FranceNew cli","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GT","BK4585","LENZ","BK4119","BK4139","EMA","GCC","BK4539","BK4081","COAG","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651810256","title":"Hemab Therapeutics' Sutacimig Continues to Support Durable Bleed Reduction, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2651810256","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651810256?lang=en_us&edition=fundamental","pubTime":"2026-07-14 22:50","pubTimestamp":1784040612,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics' (COAG) sutacimig continues to support clinically meaningful and durable bleed reduction in Glanzmann thrombasthenia, based on the company's phase 2 long-term extension data, Wedbus","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","LENZ","COAG","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651080481","title":"Hemab Therapeutics presents sutacimig data at ISTH Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2651080481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651080481?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:50","pubTimestamp":1784029816,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics (COAG) presented clinical and preclinical data from sutacimig in GT and FVIID at the International Society on Thrombosis and Hae...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-presents-sutacimig-data-at-isth-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-presents-sutacimig-data-at-isth-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COAG","BK4539","BK4119","BK4007","GT","BK4585","LENZ","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651110938","title":"Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2651110938","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651110938?lang=en_us&edition=fundamental","pubTime":"2026-07-13 22:42","pubTimestamp":1783953729,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics'  HMB-002 is particularly well suited for Type 1 von Willebrand disease patients despite encouraging early data from Incyte's  latarcibart, Wedbush Securities said in a Monday note.The investment firm said in the research note that HMB-002 is particularly well suited for Type 1 patients, who comprise about 75% of the diagnosed Von Willebrand disease population, because it targets restoration of the underlying von Willebrand factor.The analysts noted that HMB-002 has demonstrated encouraging preliminary clinical efficacy, with eight of nine evaluable patients experiencing no treated bleeding events during the 28 days following a single dose.Multidose Part B data expected in late 2026 or early 2027 should provide the first assessment of whether the early efficacy observations translate into durable bleed reduction with chronic dosing, according to the note.Wedbush reiterated its outperform rating and $55 price target on the stock.Shares of Hemab were up 2% in Monday tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4532","BK4550","COAG","BK4139","BK4585","LENZ","IDNA","BK4588","INCY","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651112898","title":"Hemab Therapeutics Holdings Inc : Jefferies Raises Target Price to $47 from $39","url":"https://stock-news.laohu8.com/highlight/detail?id=2651112898","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651112898?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:26","pubTimestamp":1783949165,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650816305","title":"Hemab Therapeutics presents new clinical data from HMB-002 in VWD","url":"https://stock-news.laohu8.com/highlight/detail?id=2650816305","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650816305?lang=en_us&edition=fundamental","pubTime":"2026-07-12 21:45","pubTimestamp":1783863909,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics (COAG) presented new clinical data from HMB-002 in Von Willebrand disease, VWD, and announced the HMB-003 program at the Interna...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-presents-new-clinical-data-from-hmb-002-in-vwd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-presents-new-clinical-data-from-hmb-002-in-vwd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","COAG","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646350582","title":"Hemab Therapeutics Plans First-in-human Study of Hmb-003 Plasmin Inhibitor in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2646350582","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646350582?lang=en_us&edition=fundamental","pubTime":"2026-06-26 21:00","pubTimestamp":1782478858,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics plans first-in-human study of HMB-003 plasmin inhibitor in 2H 2026Hemab Therapeutics flagged new first-in-human results for HMB-002 in Von Willebrand disease, scheduled for presenta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDLlZVT7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4585","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00B64PRP62.GBP","BK4139","NDAQ","LU2095319765.USD","COAG","IE00BGHQF748.EUR","BK4112","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644776864","title":"Major Investor Quietly Ramps Up Stake in Hemab Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2644776864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644776864?lang=en_us&edition=fundamental","pubTime":"2026-06-18 10:06","pubTimestamp":1781748394,"startTime":"0","endTime":"0","summary":"New insider activity at Hemab Therapeutics Holdings, Inc. ( ($COAG) ) has taken place on June 17, 2026. Ra Capital Management, LLC, a significant s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ramps-up-stake-in-hemab-therapeutics-insider-trading-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ramps-up-stake-in-hemab-therapeutics-insider-trading-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","COAG","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644872202","title":"RA Capital Management reports Hemab Therapeutics common stock purchase worth $1.69 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644872202","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644872202?lang=en_us&edition=fundamental","pubTime":"2026-06-18 06:25","pubTimestamp":1781735103,"startTime":"0","endTime":"0","summary":"RA Capital Management, a 10% owner of Hemab Therapeutics Holdings, reported open-market purchases of 67,669 common shares at about $24.89-$24.98.RA Capital Healthcare Fund’s stake rose to 6,444,637 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL11ZqyF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management reports Hemab Therapeutics common stock purchase worth $1.69 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644710949","title":"Hemab Therapeutics Hldgs Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2644710949","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644710949?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:24","pubTimestamp":1781691840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/COAG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 06:24 ET (10:24 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","COAG","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}